Company Overview and News
SINGAPORE / ACCESSWIRE / September 24, 2018 / BitMax.io is a new digital asset trading platform that provides cryptocurrency trading services to a wide range of clients, including professional traders, institutional investors, and private investors. The platform has almost 20,000 users globally with 16 active trading pairs and additional listings undergoing the approval process.
Deutsche Bank analyst Matthew Niknam added AT&T Inc. T, +0.16% shares to the firm's "short-term buy" list on Monday, due to what he deems an "attractive" set-up heading into the company's next earnings report. He sees "improving second derivative trends" for AT&T's two largest segments, wireless and entertainment. Niknam maintained his hold rating on the stock over the medium term, writing that concerns about linear video as well as Time Warner risks are issues that "cannot be ignored.
DB TWX VZ TWC VZA
FRANKFURT, Germany (AP) — Germany's financial regulator has ordered Deutsche Bank to install a special monitor to oversee the implementation of safeguards against money laundering.
FRANKFURT (Reuters) - Germany’s financial watchdog has ordered Deutsche Bank (DBKGn.DE) to do more to prevent money laundering and “terrorist financing,” and has appointed a third party to assess progress.
FRANKFURT (Sept 24): Germany's financial watchdog BaFin has ordered Deutsche Bank to take measures to prevent money laundering and "terrorist financing" and has appointed a special representative to report and assess progress.
LONDON (Reuters) - AstraZeneca’s diabetes drug Farxiga met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients, potentially distinguishing it from rivals in a crowded marketplace.
LONDON, Sept 24 — The British pound bounced half a per cent to above US$1.31 (RM5.41) today after a big selloff in the previous session, helped by comments from Britain’s Brexit Secretary that a deal with the European Union was still possible.
Rising prices could be here to stay as the ageing population across much of the world pushes them up, analysts at Deutsche Bank have warned.
This week, market chatter centered around the relative merits of shifting to an ex-U.S. tilt in your asset allocation strategy.
With the markets at all-time highs, it is prime season for initial public offerings (IPOs) and companies can get more bang for their buck. There were a couple major IPOs this past week that lived up to the hype and then some, and one that floundered.
EB DB BNPQY LLY BNPQF BNPZY XYF ELAN MS
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to DB / Deutsche Bank AG on message board site Silicon Investor.
as of ET